Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunosuppression as a desired pharmacological effect.

G Dickneite, R Kurrle, F R Seiler

    Behring Institute Mitteilungen
    |May 1, 1984
    PubMed
    Summary

    Aclacinomycin A (ACM), an antineoplastic antibiotic, effectively suppresses B-cell mediated humoral immune responses. This immunosuppressive action, particularly on antibody production, underlies its beneficial effects in certain autoimmune diseases.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Four-factor prothrombin complex concentrate reverses apixaban-associated bleeding in a rabbit model of acute hemorrhage.

    Journal of thrombosis and haemostasis : JTH·2015
    Same author

    Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP).

    Journal of thrombosis and haemostasis : JTH·2014
    Same author

    Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model.

    Journal of thrombosis and haemostasis : JTH·2012
    Same author

    Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.

    Journal of thrombosis and haemostasis : JTH·2012
    Same author

    Anti H-2Dd alloreactivity mediated by herpes-simplex-virus specific cytotoxic H-2k T lymphocytes is associated with H-2Dk.

    Immunogenetics·2012
    Same author

    Repeated infusions of VWF/FVIII concentrate: impact of VWF:FVIII ratio on FVIII trough and peak levels in a rabbit model.

    Haemophilia : the official journal of the World Federation of Hemophilia·2011

    Area of Science:

    • Immunology
    • Pharmacology
    • Oncology

    Background:

    • Aclacinomycin A (ACM) is an antineoplastic antibiotic with potential immunomodulatory properties.
    • Understanding the impact of ACM on distinct immune responses is crucial for its therapeutic application.

    Purpose of the Study:

    • To evaluate the immunosuppressive efficacy of Aclacinomycin A (ACM) on humoral and cellular immune responses.
    • To investigate the therapeutic potential of ACM in models of B-cell mediated autoimmune diseases.

    Main Methods:

    • Assayed humoral immunity via in vitro and in vivo splenic plaque forming cells (PFC) and antibody titers.
    • Assessed T-cell mediated immunity including delayed-type hypersensitivity (DTH) reactions and cytotoxic T-lymphocyte activity.
    • Evaluated ACM's effect in graft-versus-host (GvH) disease models.

    Main Results:

    • ACM markedly inhibited both in vitro and in vivo humoral immune responses, suppressing PFC and circulating antibodies.
    • No significant effect of ACM was observed on T-cell mediated immune responses, including DTH, cytotoxic lymphocytes, skin transplantation, or experimental autoimmune encephalomyelitis (EAE).
    • ACM demonstrated a beneficial effect on two GvH models (hemolytic anemia and immune complex glomerulonephritis), which are B-cell mediated autoimmune diseases.

    Conclusions:

    • Aclacinomycin A (ACM) selectively suppresses B-cell mediated humoral immunity.
    • The therapeutic benefit of ACM in GvH disease models is attributed to its potent suppression of B-cell responses.
    • ACM holds promise as a therapeutic agent for B-cell driven autoimmune conditions.

    Related Experiment Videos